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Abstract  
Context: 
Many guidelines recommend that patients with type 2 diabetes should reduce their dietary sodium 
intake. However, the relationship between dietary sodium intake and incidence of diabetic 
complications in patients with type 2 diabetes has not been explored. 
Objective: 
To investigate the relationship between dietary sodium intake and incidence of diabetes complications. 
Design, Setting, and Participants: 
A nationwide cohort of patients with type 2 diabetes aged 40-70y with HbA1c ≥6.5%.  
Main Outcome Measures: 
After excluding non-responders to a dietary survey, 1588 patients were analyzed. Baseline dietary 
intake was assessed by the Food Frequency Questionnaire based on food groups. Primary outcomes 
were times to cardiovascular disease (CVD), overt nephropathy, diabetic retinopathy, and all-cause 
mortality.  
Results: 
Mean daily dietary sodium intake in quartiles ranged from 2.8 to 5.9g. After adjustment for 
confounders, hazard ratios (HRs) for CVD in patients in the 2nd, 3rd, and 4th quartiles of sodium 
intake compared with the 1st quartile were 1.70 (95% confidence interval, 0.98-2.94), 1.47 (0.82-2.62), 
and 2.07 (1.21-3.90), respectively (trend p<0.01). In addition, among patients who had HbA1c ≥9.0%, 
HR for CVD in patients in the top vs. bottom quartile of sodium intake was dramatically elevated 
compared with patients with HbA1c<9.0% (1.16 (0.56-2.39) and 9.91 (2.66-36.87), interaction 
p<0.01). Overt nephropathy, diabetic retinopathy, and all-cause mortality were not significantly 
associated with sodium intake. 
Conclusions: 
Findings suggested that high dietary sodium intake is associated with elevated incidence of CVD in 
patients with type 2 diabetes and that there is a synergistic effect between HbA1c values and dietary 
sodium intake for the development of CVD. 
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Introduction  
Reduction of dietary salt intake is encouraged in guidelines for diabetes care in many 
countries (1-4), with various goals being set for daily intake of sodium (>2.3 g/day in the USA (1), 
>2.36 g/day in Europe (2), and >3.9 g/day in Japan (3).) However, current guidelines for salt reduction 
are based on epidemiological studies of participants without diabetes. In the position statement by the 
American Diabetes Association in 2013 (1), its recommendation for sodium reduction was based on 
the Dietary Approaches to Stop Hypertension diet designed for participants without diabetes in which 
sodium intake is limited to less than 1.5 g/day, consumption of fruits, vegetables, and low-fat dairy 
products is increased, and excessive alcohol consumption avoided, with the possible result of weight 
reduction (5).  
Some relatively small short-term studies of patients with type 2 diabetes reported that dietary 
sodium restriction conferred a modest reduction in blood pressure (6) and that salt supplementation 
reduced the antihypertensive efficacy of blood pressure-lowering agents (7). In addition, there are few 
longitudinal studies of sodium intake in patients with diabetes and the results are limited to the 
association between 24-h urinary sodium excretion and the incidence of mortality and end-stage renal 
disease (8, 9). Therefore, epidemiological evidence of the relationship between dietary sodium intake 
and the incidence of diabetes complications in patients with type 2 diabetes remains uncertain. 
Thus, in this study, we investigated the association between dietary sodium intake and the 
incidence of diabetes complications including cardiovascular disease (CVD), overt nephropathy, and 
diabetic retinopathy as well as all-cause mortality in patients with type 2 diabetes in the large 
nationwide multicenter cohort of the Japan Diabetes Complications Study (JDCS).   
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Materials and Methods 
Study cohort 
The present analysis was conducted as part of the JDCS, a multicenter prospective study on 
the incidence of and risk factors for macro- and microvascular complications among Japanese patients 
with type 2 diabetes from outpatient clinics in 59 university and general hospitals. The primary results 
(10) of the JDCS were described elsewhere. Eligibility criteria were previously diagnosed individuals 
with type 2 diabetes aged 40–70 years whose HbA1c levels were ≥6.5% and were diagnosed by 
fasting blood sugar or the 75g oral glucose tolerance test according to values established by the Japan 
Diabetes Society (JDS) and assays that were standardized by the Laboratory Test Committee of the 
JDS, which is almost identical in terms of cut-off values for glucose levels to those of the World 
Health Organization.  
Figure 1 shows the flow diagram of the JDCS. From January 1995 to March 1996, 2205 
patients were initially registered in the JDCS. Of the 2033 patients who met the eligibility criteria 
described above, 1588 patients responded to a baseline dietary survey. There was no notable 
difference in baseline characteristics between responders and non-responders (11).  
The original primary endpoints of the JDCS were micro- and macrovascular complications. 
The following patient groups were followed as to whether or not they developed either CVD, 
nephropathy or retinopathy. The CVD group consisted of 1414 patients after excluding patients with 
impaired glucose tolerance, a history of angina pectoris, myocardial infarction, stroke, peripheral 
artery disease, familial hypercholesterolemia, type III hyperlipidemia (diagnosed by broad beta band 
on electrophoresis), or nephrotic syndrome (urine protein >3.5 g/day and serum total protein <6.0 
mg/dL or serum creatinine levels >1.3 mg/dl (120 µmol/L) at baseline. The overt nephropathy group 
consisted of 1330 patients after excluding those with impaired glucose tolerance, a history of 
non-diabetic nephropathy, nephrotic syndrome, serum creatinine levels >120 μmol/l, or mean values 
of two spot urine examinations for an albumin excretion rate of <150 mg/g creatinine. The 
retinopathy-incident group consisted of 978 patients after excluding those with impaired glucose 
tolerance, a history of retinopathy, or a major ocular disease (e.g., glaucoma, dense cataract, or history 
of cataract surgery). We analyzed follow-up data collected until March 2003.  
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The protocol for the study, which is in accordance with the Declaration of Helsinki and the 
Ethical Guidelines for Clinical/Epidemiological Studies of the Japanese Ministry of Health Labor and 
Welfare, received ethical approval from the institutional review boards of all of the participating 
institutes. Written informed consent was obtained from all enrolled patients. 
 
Outcome measures 
Macroangiopathy endpoints included the incidence of definite coronary heart disease (angina 
pectoris or myocardial infarction) or stroke. The diagnosis of angina pectoris and myocardial 
infarction was according to criteria defined by the WHO/MONICA (Multinational Monitoring of 
Trends and Determinants in Cardiovascular Disease) project, and the diagnosis of stroke was 
according to guidelines defined by the Ministry of Health, Labour and Welfare of Japan (12). 
Adjudication of endpoints was made by a central committee comprised of experts in each 
complication based on additional data such as a detailed history, sequential changes in ECG and serum 
cardiac biomarkers, and results of coronary angiography or brain imaging. The nephropathy endpoint 
was defined as the development of overt nephropathy (spot urinary albumin excretion >300 mg/g 
creatinine in two consecutive samples). Diabetic retinopathy was evaluated by qualified 
ophthalmologists at each institute using the following classification designed for this research: Stage 0, 
no retinopathy; Stage 1, hemorrhage and hard exudates; Stage 2, soft exudates; Stage 3, intraretinal 
microvascular abnormalities and venous changes including beading, loop, and duplication; and Stage 4, 
new vessels, vitreous hemorrhage, fibrous proliferation, and retinal detachment. The retinopathy 
endpoints were (i) development of retinopathy (from Stage 0 to any other stage confirmed in two 
continuous years) and (ii) progression from Stage 1 to Stage 3 or 4. 
 
Dietary assessment 
Nutritional and food intakes were assessed by the Food Frequency Questionnaire based on 
food groups (FFQg) at baseline and 5 years after registration. In brief, the FFQg elicited information 
on the average intake per week of 29 food groups and 10 kinds of cookery in commonly used units or 
portion sizes. After participants completed the questionnaire, a dietitian reviewed the completed 
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questionnaire with the participant. The FFQg was externally validated by comparison with dietary 
records for 7 continuous days of 66 subjects aged 19-60 years (13). The ratios of the estimates 
obtained by the FFQg against those by the dietary records ranged from 72% to 121% (average 104%). 
The correlation coefficient between the FFQg and dietary records for sodium intake was 0.43. We 
used standardized software for population-based surveys and nutrition counseling in Japan 
(EIYO-KUN v.4.5, manufactured at the site of the Shikoku University Nutrition Database) based on 
Standard Tables of Food Composition in Japan (14) edited by the Japanese Ministry of Education, 
Culture, Sports, Science, and Technology to calculate nutrient and food intakes. 
 
Statistical analysis 
Patient characteristics were described as mean ±SD, median, interquartile range, or 
percentage. Univariate and multivariate Cox regression analyses were used to estimate the adjusted 
hazard ratios (HR) and 95% CI for the incidence of CVD, overt nephropathy, and diabetic retinopathy 
and total mortality in relation to sodium intake. Multivariate adjusted analyses were conducted with 
adjustment for age, sex, body mass index (BMI), HbA1c, diabetes duration, LDL cholesterol, HDL 
cholesterol, log-transformed triglycerides, treatment by insulin, treatment by lipid-lowering agents, 
current smoker, alcohol intake, energy intake, sodium intake, and physical activity. In addition to the 
multivariate adjustment, we made further adjustments for systolic blood pressure and the use of 
antihypertensive agents. All p-values are two-sided, and the significance level is 0.05. All statistical 
analyses and data management were conducted at a central data center using SAS ver. 9.2 (SAS 
Institute Inc., Cary, NC, USA).
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Results 
The baseline characteristics and daily dietary intake of the 1588 patients according to 
quartiles of total sodium intake are shown in Table 1. Mean daily dietary sodium intake across 
quartiles ranged from 2.8 to 5.9 g and mean energy intake across quartiles ranged from 1470 to 2010 
kcal. Differences in the proportions of fat, protein, and carbohydrate as percentages of energy supply 
were small from the first to the fourth quartile of sodium intake although significant differences were 
observed (p <0.01, <0.01, and <0.01, respectively). Patients in higher quartiles included significantly 
more men, and physical activity, alcohol intake, and energy intake were significantly greater in the 
higher quartiles. However, there were no significant trends in BMI, blood pressure, lipids, and 
medications. There were no differences in HbA1c values among quartiles and the HbA1c levels were 
well controlled.  
During the 8-year follow-up with a follow-up rate of 76.0%, incidents according to the first to 
fourth quartiles of sodium intake were 23, 36, 32, and 41 for CVD, 26, 13, 26, and 18 for overt 
nephropathy, and 75, 66, 71, and 73 for diabetic retinopathy, respectively. Deaths according to the 
quartiles of sodium intake were 22, 23, 11, and 19, respectively. The crude incidence rates per 1000 
patient-years of CVD, overt nephropathy, and diabetic retinopathy were 13.61, 8.70, and 42.49, 
respectively. The mortality rate per 1000 patient-years was 6.68. There was no notable difference in 
baseline characteristics between patients who completed the 8-year follow-up and the other patients 
(11).  
Table 2 shows HRs for dietary sodium intake estimated by Cox regression models unadjusted 
(top model), adjusted for risk factors (middle model), and further adjusted for SBP and the use of 
antihypertensive agents (bottom model). In confounder-adjusted Cox regression, sodium intake was 
associated with an increment of incident CVD (trend p =0.03). The adjusted HR for CVD in the fourth 
quartile compared with the first quartile was 2.07 (95% CI 1.16-3.71, p =0.01). In another Cox 
regression model with the same adjustment factor but with a linear term for sodium intake, the 
adjusted HR for a 1 g per day increase in sodium intake was 1.20 (95% CI 1.03-1.41, p =0.02). This 
association remained substantially unchanged even after further adjustment for SBP and the use of 
antihypertensive agents. There were no significant trends among overt nephropathy, diabetic 
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retinopathy, and mortality (Table 2).  
Figure 2 shows results of subgroup analysis according to risk factors for CVD. Patients with 
HbA1c ≥9.0% who were in the top quartile of sodium intake had a significantly higher increase in risk 
of CVD due to sodium intake than patients with HbA1c <9.0% in the top quartile of sodium intake 
(1.58 (0.81-3.07) and 16.14 (2.86-91.19), interaction p <0.01). No notable differences were observed 
in overt nephropathy, diabetic retinopathy, and mortality. A significant effect modification was also 
observed if HbA1c was classified at 8.5% (1.21 (0.57-2.60) and 5.38 (1.86-15.55), interaction p= 0.02), 
but the interaction test was not significant if HbA1c was classified at 8.0% (2.00 (0.82-4.91) and 2.47 
(1.12-5.43), interaction p= 0.58). Table 3 shows the incidence of CVD for quartiles of sodium intake 
according to the HbA1c level. When limited to patients who had high HbA1c levels ≥9.0%, sodium 
intake was found to be associated with a dramatically increased incidence of CVD, and the adjusted 
HR for CVD of quartiles of sodium intake were 3.52 (0.95-13.09), 3.75 (0.95-14.83), and 9.91 
(2.66-36.87), respectively, for Q2, Q3, and Q4 compared with Q1 (trend p <0.01, interaction p< 0.01). 
However, there was no significant difference between quartiles of sodium intake when analysis was 
restricted to patients who had HbA1c levels <9.0%.  
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Discussion 
Many guidelines for diabetes care in many countries (1-4) recommend a reduction in dietary 
sodium intake; however, detailed evidence regarding the relationship between dietary sodium intake 
and the incidence of diabetes complications in patients with type 2 diabetes is sparse. This 8-year 
follow-up study of Japanese patients with type 2 diabetes revealed that those who consumed an 
average of 5.9 g of sodium per day had about a 2-fold higher risk of CVD than those who consumed 
an average of 2.8 g/day, although there were no significant associations of sodium intake with overt 
nephropathy, diabetic retinopathy, and all-cause mortality. These results of this longitudinal study 
show that high dietary sodium intake is associated with an elevated incidence of CVD in patients with 
type 2 diabetes, which supports current guidelines for patients with diabetes (1-4). 
In addition, our study observed that among patients who had high HbA1c levels ≥9.0%, the 
HR for CVD in patients in the top vs. the bottom quartile of sodium intake was dramatically elevated 
compared with patients with HbA1c levels <9.0% (1.16 (0.56-2.39) and 9.91 (2.66-36.87), interaction 
p <0.01). This tendency was also clearly observed when the association between sodium intake and 
CVD risk was considered linearly (trend p < 0.01, interaction p <0.01). It is well known that poor 
glycemic control leads to an increase in diabetes complications, and a previous meta-analysis reported 
that the risk of CVD in patients with type 2 diabetes was associated with an 18% increase for each 1% 
point increase in HbA1C (15). Another previous meta-analysis that targeted the general population 
also reported that higher sodium intake was associated with a greater risk of CVD (1.14, 0.99-1.32, Pp 
=0.07) (16) though the differences between the highest sodium intake and lowest sodium intake 
ranged widely from 1.0 g/day to 3.45 g/day. In comparison with the results of our present study and 
this previous study, patients in the JDCS with poorly controlled HbA1c (HbA1c ≥9.0%) had a 
particularly high incidence of CVD compared with that of the general population. Therefore, it is 
speculated that there was a synergistic effect between the HbA1c level and dietary sodium intake for 
the development of CVD. This finding indicated that a long-term reduction of dietary sodium intake is 
particularly important in those with poorly controlled blood glucose. 
 
The current goals for daily intake of dietary sodium in guidelines are below 1.5 g/day in the 
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USA (1), 2.36 g/day in Europe (2), and 3.9 g/day in Japan (3). Comparing these guidelines with the 
lowest quartile of sodium consumption in the JDCS patients (2.8 g/day), the JDCS patients still had a 
higher sodium intake compared with USA and European guidelines (+0.5 g/day and +0.44 g/day, 
respectively) even in the lowest quartile; however, intake was lower compared with Japanese 
guidelines (-1.1 g/day), a value that is similar to the 2nd quartile of sodium consumption in the JDCS 
patients. According to the distribution of mean dietary sodium intake, the mean sodium intake of the 
JDCS patients was 4.2 g/day and their intake was lower than that in the general Japanese population 
(4.6 g/day) (17) and higher than that in the US and UK general populations (3.6 and 3.4 g/day, 
respectively) (18), as well as a diabetic population in the US (2.5-3.4 g/day) (19). Further studies are 
needed to clarify whether medical nutritional treatment that restricts sodium intake to values according 
to USA and European guidelines would reduce incident CVD among persons with diabetes. 
As shown above, JDCS patients in the bottom quartile of sodium intake had a low risk of 
CVD although their sodium intake was not as low as recommended in European guidelines (1, 2). 
Additionally, patients in the lower quartiles of sodium intake had significantly lower intakes of alcohol 
and energy than those in the higher quartiles of sodium intake. However, our current study showed 
that the relationship between sodium intake and the incidence of CVD was independent of alcohol and 
energy intakes because this relationship was still observed even after adjustment for alcohol and 
energy intake and when subgroup analysis was conducted according to alcohol and energy intake. It is 
well known that modifications of alcohol and energy intake are beneficial for diabetes management (1). 
It was reported that salted food acts to drive overeating and weight gain (20). Actually, some 
interventional studies have shown that a sodium-restricted diet decreased total energy intake (21, 22). 
Also, it was reported that sugar-sweetened beverage consumption was increased by 17 g/day with each 
additional 0.4 g/day of sodium intake, although this result was provided from underage participants 
(23). In addition, an interventional study showed that alcohol intake decreased under a 
sodium-restricted diet in men (22). We had previously reported that JDCS male patients consumed 
approximately 8-fold more alcoholic beverages than the female patients (115 and 14 g/day, 
respectively) (24). From our current results it might be said that reduction in dietary salt intake would 
also play a role in making medical nutritional therapy more effective by a reduction in alcohol and 
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energy intake. However, this study cannot show the effects of alcohol and energy intake on diabetes 
complications and all-cause mortality. 
 
Our results showed that there was no significant difference between sodium intake and the 
incidence of overt nephropathy and diabetic retinopathy. In general, a reduction in dietary salt intake is 
recommended in order to prevent or slow the development of diabetic nephropathy. However, in a 
previous cohort study of patients with type 1 diabetes, urinary sodium excretion was inversely 
associated with end-stage renal disease (9); therefore, results are inconsistent regarding the 
relationship between sodium intake and renal disease. Given the unique phenomenon in patients with 
diabetes that involves an anomalous tendency for the glomerular filtration rate in the diabetic kidney 
to vary inversely with salt intake, as observed in rodents and humans with diabetes (25, 26), it might 
be important to take into account the differences in the micro- and macrovasculature because the 
influence of sodium intake on the micro- and macrovasculature has complex aspects from a biological 
viewpoint.  
Confusing results of the association between all-cause mortality and sodium intake were 
obtained in previous studies. For example, Finnish patients with type 1 diabetes with the highest as 
well as the lowest daily urinary sodium excretion had reduced survival (9). Another study targeting 
patients with type 2 diabetes in Australia reported that lower daily urinary sodium excretion was 
paradoxically associated with increased all-cause and cardiovascular mortality (8). On the other hand, 
in JDCS patients there was not a significant difference between all-cause mortality and sodium intake. 
A possible reason for such inconsistent results might be that the large differences in the background of 
patients in each study such as ethnicity, age, duration of diabetes, body weight, control of blood 
pressure, and serum lipid values influenced the results. Further studies are needed to clarify the 
association between daily sodium intake and mortality risk based on a careful consideration of the 
characteristics of patients. 
Another important finding of this study was that the mean BMI of the JDCS patients was 
within normal range and was much lower than in Western diabetic patients (19, 27-29). In terms of the 
biological aspects of ethnic differences, it is known that Asian people are more susceptible to 
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pancreatic β-cell secretory defects and pronounced dysfunction in early insulin secretion than 
Western people (30). In contrast, among Asian populations, the proportion of body fat and prevalence 
of prominent abdominal obesity are higher than in individuals of European origin with similar BMI 
values (30). In addition, the JDCS patients consumed a “high-carbohydrate low-fat” diet compared 
with Western patients with diabetes (24), and dietary sodium consumption in JDCS patients was 
generally higher than in Western general and diabetic populations as well as in the Japanese general 
population (17,18,19,24). The proportion of fat consumption by the JDCS patients met the definition 
of low fat intake reported in previous studies, which might improve serum triglyceride and cholesterol 
levels (31, 32). That might be the reason that the JDCS patients and Western patients with type 2 
diabetes had similar blood cholesterol levels although the proportion of JDCS patients treated with 
lipid-lowering agents was half that of Western patients with type 2 diabetes compared with data 
obtained by a previous longitudinal study (8). Further studies are required to clarify the mechanism of 
the development of type 2 diabetes in consideration of an ethnic-specific constitution, and it should be 
investigated whether results of dietary assessments and actual food intake differ consistently between 
Asian and Western patients with diabetes. 
 
To the best of our knowledge, this is the first study on dietary sodium intake and the 
incidence of diabetes complications in which patients with type 2 diabetes were prospectively 
registered based on their HbA1c levels and not retrospectively selected based on self-reported diabetes 
status. Other strengths include treatment and follow-up plans that were conducted in institutes 
specializing in diabetes care and adjudication of cardiovascular events by an independent central 
committee. 
Limitations of this study must be considered. First, the potential for bias, such as 
measurement errors in dietary assessments, confounding factors, and informative censoring, cannot be 
ruled out entirely. We observed significant differences in age, sex, treatment by insulin, physical 
activity, and dietary intake across sodium intake (Table 1). In our analysis, these confounders were 
adjusted using Cox regression, but the estimated effects of sodium still can be biased because of 
residual confounding or unmeasured confounders. With regard to informative censoring, we found no 
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notable difference in baseline characteristics between patients who completed the 8-year follow-up 
and the other patients (11). Second, as an observational study rather than a randomized trial, we could 
not conclude cause-effect relationships as to whether medical nutritional treatment encouraging 
sodium reduction would reduce incident CVD in clinical practice. Third, our study did not observe any 
significant association between blood pressure and dietary sodium intake. The percentage of patients 
treated by antihypertensive agents was similar in each quartile of dietary sodium intake. Given these 
results, a possible explanation may be that chronic high blood pressure could have been compensated 
for by increasing doses of antihypertensive drugs. Another limitation is the accuracy of diabetic 
retinopathy staging based on clinical diagnosis compared with staging based on seven-field stereo 
fundus photography. Finally, our results may not be generally applicable to populations with different 
lifestyles or genetic factors. For example, our study did not include the very well controlled patients 
whose HbA1c value was less than 6.5%. Additionally, the JDCS patients and Western patients with 
type 2 diabetes had similar blood cholesterol and triglyceride levels although the proportion of JDCS 
patients treated with lipid-lowering agents was half as frequent as that of Western patients (8). Also, 
the JDCS patients consumed a “high-carbohydrate low-fat” diet compared with Western patients with 
diabetes (24), and dietary sodium consumption in Japanese was generally higher than in Western 
people (17,18,19,24). In addition, BMI and body weight are markedly different between patients in 
Japan and Western countries (33), and Asian patients have a much lower risk of CVD compared with 
Western patients and higher risk of end-stage renal disease (34). The contribution of such differences 
in patients’ characteristics remains uncertain. Considering ethnic-specific characteristics and large 
inter-cultural differences is important in exploring effective medical nutritional therapy and further 
research is needed.  
 
In conclusion, we found that high dietary sodium intake was associated with an elevated 
incidence of CVD in Japanese patients with type 2 diabetes and the association was synergistically 
strengthened when the patients with type 2 diabetes were limited to those whose blood glucose was 
poorly controlled. It was suggested that dietary salt restriction as medical nutritional treatment would 
be useful to prevent complications of diabetes in patients with type 2 diabetes.
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Table 1. Baseline characteristics and nutritional intakes of the 1588 patients with type 2 diabetes 
according to quartiles of sodium intake. 
  Q1 (N=397) Q2 (N=397) Q3 (N=396) Q4 (N=398)   
  mean SD mean SD mean SD mean SD Trend p 
Sodium intake at registration (g) 2.8  ±0.4  3.8  ±0.2  4.5  ±0.2  5.9  ±0.8  <0.01 
Sodium intake at 5 y after registration 
(g) 
3.3 ±1.2  3.8  ±1.3  4.4  ±1.5  4.6  ±1.8  <0.01 
Age (y) 58.1  ±7.4  58.6  ±6.9  59.0  ±6.8  59.1  ±6.4  0.03  
Women (%) 49.6%   51.4%   47.2%   42.0%   0.02  
HbA1c in NGSP value (%) 7.9  ±1.3  7.9  ±1.3  7.9  ±1.3  7.9  ±1.3  0.96  
HbA1c (mmol/mol) 67.0 ±14.1 67.4 ±14.0 67.2 ±15.0 67.0 ±14.6 0.96 
Years after diagnosis (y) 11.0  ±7.2  11.2  ±7.1  10.8  ±7.0  10.9  ±7.0  0.65  
Body mass index (kg/m
2
) 22.8  ±2.9  23.1  ±3.1  23.0  ±2.9  23.0  ±2.9  0.31  
Systolic blood pressure (mmHg) 131.8  16.4  131.8  16.5  130.6  16.2  132.6  15.5  0.76  
Diastolic blood pressure (mmHg) 77.1  10.3  76.1  10.1  75.9  9.5  77.5  9.6  0.66 
Pulse pressure (mmHg) 54.7  13.3  55.7  13.7  54.7  13.7  55.1  13.4  0.96 
Mean blood pressure (mmHg) 95.3  11.0  94.7  10.9  94.1  10.3  95.9  10.1  0.66 
Serum LDL-cholesterol (mmol/L) 3.18 ±0.81 3.22 ±0.80 3.13 ±0.86 3.12 ±0.87 0.12 
Serum HDL-cholesterol (mmol/L) 1.41 ±0.48 1.42 ±0.41 1.42 ±0.42 1.39 ±0.44 0.42  
Serum triacylglycerol (mmol/L) a 1.16 ±0.81 1.11 ±0.81 1.07 ±0.85 1.16 ±0.75 0.42  
Urine ACR (mg/gCre) a 16.2  ±27.5  17.4  ±29.5  16.6  ±31.4  17.9  ±33.9  0.89  
eGFR (mL/min/1.73m
2
) 86.0  ±28.9  88.7  ±30.0  86.9  ±30.1  87.8  ±30.5  0.59  
Treated by insulin (%) 23.2%   23.2%   19.7%   16.3%   0.01  
Treated by OHA without insulin (%) 64.7%   65.5%   64.4%   67.8%   0.44  
Treated by antihypertensive agents 
(%) 
30.3%   28.5%   22.8%   26.4%   0.08  
Treated by lipid-lowering agents (%) 25.5%   26.3%   25.0%   21.6%   0.18  
Current smoker (%) 32.8%   26.1%   25.9%   27.6%   0.12  
Alcohol intake (g) 82.0  ±145.4  76.3  ±144.6  91.2  ±183.6  107.7  ±171.1  0.01  
Alcohol drinker (%) 36.5%  38.0%  37.7%  43.4%  0.07 
Physical activity (kJ/d) a, b 503.4  ±1119.0  620.9  ±974.0  590.1  ±1022.8  613.8  ±1319.5  <0.01 
Energy intake (kcal) 1469.5  ±327.0  1644.8  ±314.2  1828.5  ±341.6  2012.2  ±438.8  <0.01 
Protein (%energy) 16.0  ±2.3  16.5  ±2.2  17.0  ±2.2  17.3  ±2.4  <0.01 
Fat (%energy) 25.0  ±5.0  25.7  ±4.9  25.8  ±4.3  25.8  ±4.7  <0.01 
Carbohydrate (%energy) 55.6  ±6.4  54.9  ±6.1  54.3  ±5.7  54.0  ±6.4  <0.01 
a Median±interquartile range 
b Leisure-time physical activity was assessed at baseline by a self-administered questionnaire, which was almost 
identical to that used and validated in the Health Professionals’ Follow-up Study (35). Patients were asked the 
average frequency (times/week) and duration (minutes/time) spent on normal walking, brisk walking, jogging, 
golfing, tennis, swimming, aerobics dancing, cycling, and other miscellaneous exercise (specified by each 
patient). The duration spent for each activity in min/time was multiplied by its typical energy expenditure 
expressed in metabolic equivalents (METs) based on the newest compendium of Ainsworth (36), then summed 
for all activities to yield a MET-hour score/week. One MET, the energy expended by sitting quietly, is 
equivalent to 3.5 ml of oxygen uptake/kg of body weight/min or 1 kcal/kg of body weight/h. 
Abbreviations: ACR, albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate; OHA, oral 
hypoglycemic agent. 
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Table 2. Cox regression analysis of diabetes complications and all-cause mortality according to quartiles of sodium intake. 
  Q1 Q2 Q3 Q4   
 Mean SD mean SD  mean SD  mean SD   
Sodium intake (g) 2.8  ±0.4  3.8  ±0.2    4.5  ±0.2   5.9  ±0.8    
Sodium at 5 y after registration (g) 3.3 ±1.2 3.8 ±1.3  4.4 ±1.5  4.6 ±1.8   
  HR   HR 95%CI p HR 95%CI p HR 95%CI p Trend p 
Cardiovascular disease (N=1414)                         
Events/Patients 23/354   36/350     32/351     41/359       
Not adjusted Ref   1.65  (0.98 to 2.78) 0.06  1.35  (0.79 to 2.30) 0.28  1.73  (1.04 to 2.89) 0.03  0.08  
Adjusted a Ref   1.70  (0.98 to 2.93) 0.06  1.47  (0.82 to 2.62) 0.20  2.07  (1.16 to 3.71) 0.01  0.03  
Further adjusted b Ref   1.73  (1.00 to 3.00) 0.05  1.58  (0.88 to 2.84) 0.12  2.17  (1.21 to 3.90) 0.01  0.02  
Overt nephropathy (N=1330)                        
Events/Patients 26/322   13/337     26/340    18/331       
Not adjusted Ref   0.49  (0.25 to 0.95) 0.03  0.94  (0.54 to 1.61) 0.81  0.66  (0.36 to 1.21) 0.18  0.47  
Adjusted a Ref   0.50  (0.25 to 1.03) 0.06  1.04  (0.56 to 1.94) 0.89  0.79  (0.39 to 1.61) 0.52  0.95  
Further adjusted b Ref   0.50  (0.24 to 1.03) 0.06  1.17  (0.62 to 2.20) 0.63  0.83  (0.41 to 1.70) 0.61  0.88  
Diabetic retinopathy (N=978)                       
Events/Patients 75/241   66/244     71/258     73/235       
Not adjusted Ref   0.86  (0.62 to 1.20) 0.36  0.84  (0.61 to 1.17) 0.31  1.00  (0.72 to 1.38) 0.99  0.93  
Adjusted a Ref   0.86  (0.61 to 1.23) 0.42  0.94  (0.66 to 1.35) 0.75  1.10  (0.75 to 1.61) 0.64  0.57  
Further adjusted b Ref   0.86  (0.60 to 1.23) 0.40  0.96  (0.67 to 1.37) 0.80  1.10  (0.75 to 1.61) 0.64  0.55  
All-cause mortality (N=1588)                       
Events/Patients 22/397   23/397     11/396     19/398       
Not adjusted Ref   1.10  (0.62 to 1.98) 0.74  0.49  (0.24 to 1.01) 0.05  0.86  (0.46 to 1.58) 0.62  0.24  
Adjusted a Ref   1.03  (0.54 to 1.98) 0.92  0.56  (0.26 to 1.23) 0.15  0.82  (0.39 to 1.75) 0.61  0.37  
Further adjusted b Ref   1.02  (0.53 to 1.96) 0.95  0.58  (0.26 to 1.26) 0.17  0.81  (0.38 to 1.73) 0.59  0.36  
a Adjusted for age, sex, BMI, HbA1c, diabetes duration, LDL-cholesterol, HDL-cholesterol, log-transformed triglycerides, treatment by insulin, treatment by 
lipid-lowering agents, current smoker, alcohol intake, energy intake, and physical activity. 
b Further adjusted for systolic blood pressure and antihypertensive agents. 
22 
 
Table 3. Cox regression analysis of incident cardiovascular disease and quartile of sodium intake according to HbA1c level. 
  Q1 Q2 Q3 Q4    
HbA1C <9.0%  (N=1082) Mean SD mean SD  mean SD  mean SD   
 
Sodium intake at baseline (g) 2.8  ±0.4  3.8  ±0.2    4.5  ±0.2    5.9  ±0.8    
 
Sodium intake at 5 y after 
registration (g) 
3.3 ±1.2 3.8 ±1.1  4.3 ±1.4  4.6 ±1.7 
  
 
 HR   HR 95%CI p HR 95%CI p HR 95%CI p Trend p 
Interaction p 
Events/Patients 20/278   25/264     22/266     20/274        
Not adjusted Ref   1.44  (0.80 to 2.62) 0.23  1.13  (0.61 to 2.09) 0.69  1.00  (0.53 to 1.87) 1.00  0.78  0.09  
Adjusted a Ref   1.36  (0.73 to 2.54) 0.33  1.17  (0.60 to 2.28) 0.65  1.14  (0.55 to 2.34) 0.73  0.85 <0.01  
Further adjusted b Ref   1.40  (0.75 to 2.62) 0.29  1.21  (0.62 to 2.37) 0.57  1.16  (0.56 to 2.39) 0.70  0.82  <0.01 
HbA1C ≥9.0% (N=332) mean SD mean SD  mean SD  mean SD   
 
Sodium intake (g) 2.8  ±0.5  3.8  ±0.2    4.6  ±0.2    6.0  ±0.9    
 
Sodium intake at 5 y after 
registration (g) 
3.2 ±1.0 3.7 ±1.6  4.5 ±1.5  4.3 ±1.5 
  
 
 HR   HR 95%CI p HR 95%CI p HR 95%CI p Trend p 
 
Events/Patients 3/76   11/86     10/85     21/85       
Not adjusted Ref   3.38  (0.94 to 12.10) 0.06  2.99  (0.82 to 10.86) 0.10  7.31  (2.18 to 24.53) <0.01  <0.01  
Adjusted a Ref   3.29  (0.90 to 12.04) 0.07  2.81  (0.73 to 10.72) 0.13  7.64  (2.12 to 27.56) <0.01  <0.01  
Further adjusted b Ref   3.52 (0.95 to 13.09) 0.06  3.75  (0.95 to 14.83) 0.06  9.91 (2.66 to 36.87) <0.01 <0.01  
a Adjusted for age, sex, BMI, HbA1c, diabetes duration, LDL-cholesterol, HDL-cholesterol, triglycerides, treatment by insulin, treatment by lipid-lowering 
agents, current smoker, alcohol intake, energy intake, and physical activity. 
b Further adjusted for systolic blood pressure and antihypertensive agents.
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Figure Legends 
Figure 1. Flow diagram of JDCS  
 
Figure 2. Subgroup analysis of CVD according to background characteristics. 
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